NASDAQ:INCY - Incyte Stock Price, Price Target & More

$68.43 -0.62 (-0.90 %)
(As of 04/22/2018 04:00 PM ET)
Previous Close$68.43
Today's Range$67.7501 - $69.41
52-Week Range$61.30 - $140.11
Volume3.36 million shs
Average Volume3.38 million shs
Market Capitalization$14.49 billion
P/E Ratio106.92
Dividend YieldN/A

About Incyte (NASDAQ:INCY)

Incyte logoIncyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States. It offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera cancers; and ICLUSIG, a kinase inhibitor for the treatment of chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. The company's clinical stage products include ruxolitinib, a drug that is in pivotal Phase II clinical trial for steroid-refractory acute graft-versus-host-diseases (GVHD); and Phase II clinical trial for the treatment of essential thrombocythemia, as well as Phase III clinical trials for steroid-refractory acute and chronic GVHDs. In addition, it is developing itacitinib that is in Phase I/II clinical trial in combination with osimertinib for non-small cell lung cancer (NSCLC), as well as Phase III clinical trial for naïve acute GVHD; epacadostat that is in Phase III clinical trails for the treatment of melanoma, renal, bladder, head and neck, non-small cell lung cancers; MGA012 that is in Phase I clinical trial for solid tumors; INCB50465, which is in Phase II clinical trials for the treatment of diffuse large b-cell lymphoma, follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma; and INCB54828 that is in Phase II clinical trials for the bladder cancer, cholangiocarcinoma, and 8p11 myeloproliferative syndrome. The company markets its JAKAFI product through a network of specialty pharmacy providers and wholesalers. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Jiangsu Hengrui Medicine Co., Ltd.; Merus N.V.; Calithera Biosciences, Inc; Pfizer; and MacroGenics, Inc. Incyte Corporation was founded in 1991 and is headquartered in Wilmington, Delaware.

Receive INCY News and Ratings via Email

Sign-up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Commercial physical research


Debt-to-Equity Ratio0.01%
Current Ratio4.01%
Quick Ratio3.99%


Trailing P/E Ratio106.92
Forward P/E Ratio-427.69
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.54 billion
Price / Sales9.43
Cash Flow$0.8695 per share
Price / Cash78.70
Book Value$7.73 per share
Price / Book8.85


EPS (Most Recent Fiscal Year)$0.64
Net Income$-313,140,000.00
Net Margins-20.38%
Return on Equity-11.85%
Return on Assets-8.05%


Outstanding Shares211,800,000

How to Become a New Pot Stock Millionaire

Incyte (NASDAQ:INCY) Frequently Asked Questions

What is Incyte's stock symbol?

Incyte trades on the NASDAQ under the ticker symbol "INCY."

How were Incyte's earnings last quarter?

Incyte Co. (NASDAQ:INCY) released its quarterly earnings data on Thursday, February, 15th. The biopharmaceutical company reported $0.02 earnings per share for the quarter, topping analysts' consensus estimates of ($0.52) by $0.54. The biopharmaceutical company had revenue of $444.20 million for the quarter, compared to analysts' expectations of $435.23 million. Incyte had a negative net margin of 20.38% and a negative return on equity of 11.85%. The firm's revenue for the quarter was up 36.0% on a year-over-year basis. During the same quarter last year, the company earned $0.05 earnings per share. View Incyte's Earnings History.

When is Incyte's next earnings date?

Incyte is scheduled to release their next quarterly earnings announcement on Tuesday, May, 1st 2018. View Earnings Estimates for Incyte.

What price target have analysts set for INCY?

22 brokerages have issued 1 year target prices for Incyte's stock. Their forecasts range from $65.00 to $174.00. On average, they expect Incyte's stock price to reach $117.95 in the next twelve months. View Analyst Ratings for Incyte.

What are Wall Street analysts saying about Incyte stock?

Here are some recent quotes from research analysts about Incyte stock:
  • 1. According to Zacks Investment Research, "Incyte's Jakafi performance was strong in 2017 driven by patient demand. The sales guidance for 2018 was also impressive. Jakafi sales are expected to get a boost from the updated labels. Incyte expects Jakafi revenues in the range of $1.35-$1.4 billion in 2018, more than 20% growth over 2017. Meanwhile, the NDA for Olumiant was resubmitted and a potential approval will further boost the top line. Incyte’s pipeline is highly encouraging with promising immune therapies including epacadostat.. However, Incyte’s dependence on only Jakafi for growth is concerning. In addition, the recent failure of epacadostat study for the melanoma study with Keytruda was a big disappointment. Shares of the company have underperformed the industry in the last six months. Loss Estimates have narrowed ahead of the Q1 earnings results. The company has a mixed record of earnings surprises in recent quarters." (4/19/2018)
  • 2. Cowen Inc analysts commented, "Over the weekend Incyte presented multiple datasets from a Phase I/II trial of." (6/5/2017)

Who are some of Incyte's key competitors?

Who are Incyte's key executives?

Incyte's management team includes the folowing people:
  • Mr. Hervé Hoppenot, Chairman, Pres & CEO (Age 58)
  • Mr. David W. Gryska, Exec. VP & CFO (Age 63)
  • Dr. Reid M. Huber, Exec. VP & Chief Scientific Officer (Age 46)
  • Dr. Wenqing Yao, Exec. VP & Head of Discovery Chemistry (Age 55)
  • Dr. Steven H. Stein, Exec. VP & Chief Medical Officer (Age 51)

Has Incyte been receiving favorable news coverage?

Headlines about INCY stock have been trending positive on Sunday, Accern Sentiment Analysis reports. The research group scores the sentiment of media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Incyte earned a media sentiment score of 0.28 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 43.96 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future.

How do I buy shares of Incyte?

Shares of INCY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Incyte's stock price today?

One share of INCY stock can currently be purchased for approximately $68.43.

How big of a company is Incyte?

Incyte has a market capitalization of $14.49 billion and generates $1.54 billion in revenue each year. The biopharmaceutical company earns $-313,140,000.00 in net income (profit) each year or $0.64 on an earnings per share basis. Incyte employs 1,208 workers across the globe.

How can I contact Incyte?

Incyte's mailing address is 1801 AUGUSTINE CUT-OFF, WILMINGTON DE, 19803. The biopharmaceutical company can be reached via phone at 302-498-6700 or via email at [email protected]

MarketBeat Community Rating for Incyte (INCY)

Community Ranking:  3.6 out of 5 (star star star)
Outperform Votes:  873 (Vote Outperform)
Underperform Votes:  323 (Vote Underperform)
Total Votes:  1,196
MarketBeat's community ratings are surveys of what our community members think about Incyte and other stocks. Vote "Outperform" if you believe INCY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INCY will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Incyte (NASDAQ:INCY) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
22 Wall Street analysts have issued ratings and price targets for Incyte in the last 12 months. Their average twelve-month price target is $117.95, suggesting that the stock has a possible upside of 72.37%. The high price target for INCY is $174.00 and the low price target for INCY is $65.00. There are currently 7 hold ratings and 15 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.682.712.742.78
Ratings Breakdown: 0 Sell Rating(s)
7 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
15 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
17 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
5 Hold Rating(s)
18 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $117.95$142.3684$142.8571$144.5238
Price Target Upside: 72.37% upside64.45% upside53.35% upside27.26% upside

Incyte (NASDAQ:INCY) Consensus Price Target History

Price Target History for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Analyst Ratings History

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/17/2018Credit Suisse GroupSet Price TargetBuy$78.00LowView Rating Details
4/12/2018UBSUpgradeNeutral -> Buy$76.00LowView Rating Details
4/9/2018JPMorgan ChaseLower Price TargetOverweight -> Overweight$149.00 -> $96.00LowView Rating Details
4/9/2018Morgan StanleyLower Price TargetOverweight -> Overweight$142.00 -> $76.00HighView Rating Details
4/9/2018GabelliDowngradeBuy -> HoldMediumView Rating Details
4/9/2018NomuraLower Price TargetBuy$102.00LowView Rating Details
4/9/2018OppenheimerSet Price TargetHold$110.00 -> $65.00LowView Rating Details
4/6/2018SunTrust BanksReiterated RatingBuy$80.00LowView Rating Details
4/6/2018Raymond JamesSet Price TargetBuy$85.00HighView Rating Details
4/6/2018GuggenheimReiterated RatingBuy -> NeutralHighView Rating Details
4/6/2018William BlairReiterated RatingOutperform -> Market PerformHighView Rating Details
4/5/2018BarclaysLower Price TargetOverweight -> Overweight$165.00 -> $135.00LowView Rating Details
1/3/2018BMO Capital MarketsReiterated RatingBuy$172.00LowView Rating Details
1/2/2018CitigroupReiterated RatingMarket Perform$135.00 -> $120.00HighView Rating Details
1/2/2018Royal Bank of CanadaUpgradeSector Perform -> Outperform$136.00HighView Rating Details
12/12/2017Deutsche BankInitiated CoverageHold$106.00MediumView Rating Details
12/5/2017CowenReiterated RatingBuyLowView Rating Details
10/6/2017Goldman SachsInitiated CoverageBuy$160.00N/AView Rating Details
10/6/2017Jefferies GroupReiterated RatingBuyN/AView Rating Details
9/13/2017ArgusReiterated RatingBuy$150.00LowView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$135.00MediumView Rating Details
5/31/2017CIBCBoost Price TargetOutperform$125.00 -> $135.00LowView Rating Details
4/17/2017Piper JaffrayReiterated RatingOverweight -> Neutral$124.00MediumView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$148.00N/AView Rating Details
1/18/2017JMP SecuritiesReiterated RatingOutperform$130.00N/AView Rating Details
11/20/2016Leerink SwannReiterated RatingOutperform$101.00 -> $115.00N/AView Rating Details
6/6/2016Brean CapitalReiterated RatingBuyN/AView Rating Details
(Data available from 4/22/2016 forward)


Incyte (NASDAQ:INCY) Earnings History and Estimates Chart

Earnings by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ:INCY) Earnings Estimates

2018 EPS Consensus Estimate: $0.22
2019 EPS Consensus Estimate: $0.20
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184($0.33)$0.10($0.17)
Q2 20184($0.06)$0.39$0.10
Q3 20183$0.04$0.47$0.22
Q4 20184($0.12)$0.33$0.07
Q1 20191($0.05)($0.05)($0.05)
Q2 20191$0.20$0.20$0.20
Q3 20191$0.14$0.14$0.14
Q4 20191($0.09)($0.09)($0.09)

Incyte (NASDAQ INCY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2018($0.06)N/AView Earnings Details
2/15/2018Q4 2017($0.52)$0.02$435.23 million$444.20 millionViewN/AView Earnings Details
10/31/2017Q3 2017$0.06$0.17$360.34 million$381.50 millionViewN/AView Earnings Details
8/1/2017Q2 2017($0.05)($0.06)$318.45 million$326.40 millionViewListenView Earnings Details
5/4/2017Q1 2017($0.97)($0.96)$359.19 million$384.08 millionViewListenView Earnings Details
2/14/2017Q416$0.14$0.05$324.90 million$326.00 millionViewListenView Earnings Details
11/1/2016Q316($0.04)$0.11$260.98 million$269.50 millionViewN/AView Earnings Details
8/9/2016Q216($0.02)$0.18$236.91 million$208.00 millionViewN/AView Earnings Details
5/9/2016Q116$0.29$0.12$266.38 million$263.00 millionViewN/AView Earnings Details
2/11/2016Q415$0.09$0.29$223.54 million$243.88 millionViewListenView Earnings Details
11/3/2015Q315($0.41)($0.22)$179.30 million$187.70 millionViewN/AView Earnings Details
8/4/2015Q215($0.11)($0.04)$153.27 million$162.98 millionViewListenView Earnings Details
4/30/2015Q115($0.06)($0.11)$155.21 million$159.30 millionViewListenView Earnings Details
2/12/2015Q414($0.14)($0.22)$138.37 million$106.00 millionViewListenView Earnings Details
10/30/2014Q3$0.02$0.33$149.92 million$198.15 millionViewListenView Earnings Details
7/31/2014Q214($0.09)($0.22)$140.72 million$99.58 millionViewListenView Earnings Details
5/1/2014Q114($0.19)($0.21)$97.70 million$89.80 millionViewListenView Earnings Details
2/12/2014Q413($0.10)($0.15)$98.04 million$97.10 millionViewListenView Earnings Details
10/31/2013Q313($0.13)($0.14)$81.40 million$85.10 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.08$0.05$114.34 million$101.70 millionViewListenView Earnings Details
5/2/2013Q1 2013($0.18)($0.12)$68.16 million$71.10 millionViewListenView Earnings Details
2/14/2013Q4 2012($0.02)$0.14$92.03 million$113.80 millionViewListenView Earnings Details
11/1/2012Q312($0.21)($0.17)$60.61 million$60.50 millionViewN/AView Earnings Details
8/2/2012($0.02)$0.03ViewN/AView Earnings Details
4/26/2012($0.48)($0.36)ViewN/AView Earnings Details
2/15/2012($0.40)($0.44)ViewN/AView Earnings Details
10/27/2011($0.43)($0.42)ViewN/AView Earnings Details
7/28/2011($0.36)($0.41)ViewN/AView Earnings Details
5/3/2011($0.32)($0.21)ViewN/AView Earnings Details
2/10/2011$0.19$0.26ViewN/AView Earnings Details
11/9/2010Q3 2010($0.33)($0.26)ViewN/AView Earnings Details
8/5/2010Q2 2010($0.04)$0.02ViewN/AView Earnings Details
5/6/2010Q1 2010($0.31)($0.27)ViewN/AView Earnings Details
2/18/2010Q4 2009($0.35)($0.41)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.41)($0.39)ViewN/AView Earnings Details
7/30/2009Q2 2009($0.41)($0.41)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.42)($0.41)ViewN/AView Earnings Details
2/18/2009Q4 2008($0.47)($0.50)ViewN/AView Earnings Details
11/6/2008Q3 2008($0.50)($0.49)ViewN/AView Earnings Details
7/29/2008Q2 2008($0.50)($0.54)ViewN/AView Earnings Details
4/30/2008Q1 2008($0.47)($0.48)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.25)($0.26)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)


Incyte (NASDAQ:INCY) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Incyte (NASDAQ INCY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 17.20%
Institutional Ownership Percentage: 93.56%
Insider Trading History for Incyte (NASDAQ:INCY)
Institutional Ownership by Quarter for Incyte (NASDAQ:INCY)

Incyte (NASDAQ INCY) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/21/2018David W GryskaInsiderSell1,952$85.56$167,013.1212,922View SEC Filing  
2/21/2018Reid M HuberEVPSell1,958$85.55$167,506.90View SEC Filing  
1/5/2018David W GryskaInsiderSell6,760$98.87$668,361.2020,752View SEC Filing  
1/2/2018Vijay K IyengarEVPSell5,000$97.26$486,300.00View SEC Filing  
12/1/2017Reid M HuberEVPSell696$98.01$68,214.96View SEC Filing  
11/16/2017Paul A FriedmanDirectorSell28,507$105.24$3,000,076.68View SEC Filing  
11/2/2017David W GryskaInsiderSell3,915$105.63$413,541.45View SEC Filing  
9/18/2017Herve HoppenotPresidentSell70,502$119.45$8,421,463.90View SEC Filing  
9/14/2017Barry P FlannellyEVPSell714$124.25$88,714.5015,496View SEC Filing  
9/8/2017Bros. Advisors Lp BakerDirectorBuy100,000$132.00$13,200,000.00View SEC Filing  
9/5/2017Paul TrowerInsiderSell3,000$138.41$415,230.0014,853View SEC Filing  
9/1/2017Eric H SiegelEVPSell1,820$137.40$250,068.0023,553View SEC Filing  
8/31/2017Paula J SwainEVPSell20,000$140.00$2,800,000.0055,067View SEC Filing  
8/29/2017Steven H SteinEVPSell2,111$125.00$263,875.0018,687View SEC Filing  
8/4/2017Paul TrowerInsiderSell3,000$125.25$375,750.0011,853View SEC Filing  
8/1/2017Eric H SiegelEVPSell1,820$132.92$241,914.4023,553View SEC Filing  
7/20/2017Steven H SteinEVPSell6,485$131.09$850,118.6519,356View SEC Filing  
7/5/2017Paul TrowerInsiderSell3,000$126.18$378,540.0012,148View SEC Filing  
7/3/2017Eric H SiegelEVPSell1,820$126.20$229,684.0020,036View SEC Filing  
6/30/2017David W GryskaInsiderSell599$129.74$77,714.2619,614View SEC Filing  
6/20/2017Steven H SteinEVPSell9,883$125.00$1,235,375.0018,518View SEC Filing  
6/12/2017David W GryskaCFOSell16,756$116.60$1,953,749.6035,771View SEC Filing  
6/5/2017Paul TrowerInsiderSell3,000$132.50$397,500.0013,950View SEC Filing  
6/1/2017Eric H SiegelEVPSell1,820$130.00$236,600.0018,744View SEC Filing  
5/31/2017Jean Jacques BienaimeDirectorBuy500$131.80$65,900.004,677View SEC Filing  
5/15/2017Jean Jacques BienaimeDirectorBuy500$115.00$57,500.004,177View SEC Filing  
5/8/2017Reid M HuberEVPSell8,577$119.21$1,022,464.1744,614View SEC Filing  
5/1/2017Eric H SiegelEVPSell1,820$124.73$227,008.6018,744View SEC Filing  
4/28/2017Jean Jacques BienaimeDirectorBuy500$124.26$62,130.003,677View SEC Filing  
4/13/2017Jean Jacques BienaimeDirectorBuy1,000$139.66$139,660.003,177View SEC Filing  
4/10/2017David W GryskaInsiderSell41,528$138.00$5,730,864.0020,754View SEC Filing  
4/10/2017Eric H SiegelEVPSell4,043$140.18$566,747.7419,008View SEC Filing  
4/7/2017Jean Jacques BienaimeDirectorBuy1,000$139.48$139,480.002,177View SEC Filing  
4/7/2017Steven H SteinEVPSell32,000$137.88$4,412,160.0041,648View SEC Filing  
3/17/2017Paul A FriedmanDirectorSell50,000$148.72$7,436,000.00302,976View SEC Filing  
1/9/2017Reid M. HuberEVPSell11,739$113.55$1,332,963.45View SEC Filing  
11/9/2016Reid M. HuberEVPSell2,715$109.95$298,514.25View SEC Filing  
10/20/2016Paula J SwainEVPSell10,000$90.00$900,000.0039,248View SEC Filing  
10/7/2016Barry P FlannellyEVPSell24,204$97.00$2,347,788.0013,595View SEC Filing  
9/23/2016Paula J SwainEVPSell20,000$90.00$1,800,000.0049,248View SEC Filing  
8/2/2016Reid M. HuberEVPSell10,000$87.96$879,600.00View SEC Filing  
7/29/2016Paula J SwainEVPSell60,000$90.00$5,400,000.0089,248View SEC Filing  
3/17/2016Julian BakerDirectorBuy800,000$63.98$51,184,000.0058,632View SEC Filing  
2/25/2016Julian BakerDirectorBuy64,290$70.79$4,551,089.10View SEC Filing  
2/16/2016Julian BakerDirectorBuy887,165$69.87$61,986,218.55View SEC Filing  
2/12/2016Julian BakerDirectorBuy2,251,427$63.53$143,033,157.31View SEC Filing  
1/15/2016Paula J. SwainEVPSell13,531$76.96$1,041,345.7623,693View SEC Filing  
1/6/2016Richard S. LevyEVPSell3,937$101.86$401,022.8216,926View SEC Filing  
12/7/2015Richard S. LevyEVPSell3,937$106.18$418,030.6616,926View SEC Filing  
11/18/2015Paul A. FriedmanDirectorSell225,000$113.83$25,611,750.00297,518View SEC Filing  
11/10/2015Eric H. SiegelEVPSell2,222$104.86$232,998.923,710View SEC Filing  
11/6/2015Richard S. LevyEVPSell3,936$116.51$458,583.3616,926View SEC Filing  
11/3/2015Yao WenqingEVPSell5,786$124.78$721,977.0821,371View SEC Filing  
10/13/2015Eric H. SiegelEVPSell2,222$101.49$225,510.783,355View SEC Filing  
10/6/2015Richard S. LevyEVPSell3,937$122.29$481,455.7316,926View SEC Filing  
9/21/2015Reid M. HuberEVPSell10,000$124.29$1,242,900.0062,865View SEC Filing  
9/16/2015Eric H. SiegelEVPSell2,222$130.69$290,393.183,355View SEC Filing  
9/11/2015Richard S LevyEVPSell4,301$130.00$559,130.0016,926View SEC Filing  
9/8/2015Richard S. LevyEVPSell3,937$118.90$468,109.3021,227View SEC Filing  
8/13/2015Eric H SiegelEVPSell2,222$107.69$239,287.18View SEC Filing  
7/15/2015Richard S LevyEVPSell70,217$120.00$8,426,040.00View SEC Filing  
7/14/2015Eric H SiegelEVPSell2,222$113.61$252,441.42View SEC Filing  
7/6/2015Richard S LevyEVPSell3,937$107.00$421,259.00View SEC Filing  
6/23/2015James M DalyEVPSell11,691$108.24$1,265,433.84View SEC Filing  
6/19/2015Richard S LevyEVPSell20,000$108.13$2,162,600.00View SEC Filing  
6/12/2015Eric H SiegelEVPSell2,223$105.31$234,104.13View SEC Filing  
6/8/2015Richard S LevyEVPSell3,937$107.58$423,542.46View SEC Filing  
5/27/2015Paul A FriedmanDirectorSell196,751$107.23$21,097,609.73View SEC Filing  
5/22/2015Paul A FriedmanDirectorSell102,243$108.22$11,064,737.46View SEC Filing  
5/14/2015Eric H SiegelEVPSell2,222$104.99$233,287.78View SEC Filing  
4/23/2015James M DalyEVPSell36,941$107.67$3,977,437.47View SEC Filing  
4/17/2015Yao WenqingEVPSell7,150$102.04$729,586.00View SEC Filing  
4/14/2015Eric H SiegelEVPSell2,222$98.72$219,355.84View SEC Filing  
4/13/2015Yao WenqingEVPSell23,000$95.18$2,189,140.00View SEC Filing  
4/7/2015Yao WenqingEVPSell20,031$90.13$1,805,394.03View SEC Filing  
3/30/2015Laurent ChardonnetVPSell113,776$93.64$10,653,984.64View SEC Filing  
3/30/2015Reid M HuberEVPSell34,263$93.66$3,209,072.58View SEC Filing  
3/12/2015Barry A ArikoDirectorSell80,000$89.27$7,141,600.00View SEC Filing  
3/12/2015Eric H SiegelEVPSell2,222$89.72$199,357.84View SEC Filing  
2/25/2015Eric H SiegelEVPSell13,333$85.00$1,133,305.00View SEC Filing  
2/24/2015James M DalyEVPSell11,112$82.19$913,295.28View SEC Filing  
2/17/2015Paula J SwainEVPSell17,500$76.90$1,345,750.00View SEC Filing  
1/26/2015Eric H SiegelEVPSell13,542$79.85$1,081,328.70View SEC Filing  
1/23/2015James M DalyEVPSell11,109$77.68$862,947.12View SEC Filing  
1/20/2015Paula J SwainEVPSell17,500$74.17$1,297,975.00View SEC Filing  
1/16/2015Richard S LevyEVPSell12,000$73.07$876,840.00View SEC Filing  
1/8/2015Eric H SiegelEVPSell15,626$75.00$1,171,950.00View SEC Filing  
1/6/2015Richard S LevyEVPSell25,000$71.84$1,796,000.00View SEC Filing  
1/5/2015Paula J SwainEVPSell17,500$73.90$1,293,250.00View SEC Filing  
12/23/2014James M DalyEVPSell11,113$74.43$827,140.59View SEC Filing  
12/2/2014Schutter Richard U DeChairmanSell50,000$74.89$3,744,500.00View SEC Filing  
11/6/2014Paul A FriedmanDirectorSell185,653$67.87$12,600,269.11View SEC Filing  
10/23/2014James M DalyEVPSell11,111$53.49$594,327.39View SEC Filing  
9/23/2014James M DalyEVPSell11,111$47.65$529,439.15View SEC Filing  
9/16/2014Richard S LevyEVPSell8,000$47.58$380,640.00View SEC Filing  
8/18/2014Richard S LevyEVPSell8,000$51.97$415,760.00View SEC Filing  
7/23/2014James M DalyEVPSell11,111$48.54$539,327.94View SEC Filing  
7/16/2014Richard S LevyEVPSell8,000$48.15$385,200.00View SEC Filing  
6/23/2014James M DalyEVPSell11,111$56.03$622,549.33View SEC Filing  
6/16/2014Richard S LevyEVPSell8,000$53.88$431,040.00View SEC Filing  
6/5/2014David C HastingsCFOSell200,000$52.73$10,546,000.00View SEC Filing  
5/23/2014James M DalyEVPSell11,111$48.48$538,661.28View SEC Filing  
5/16/2014Richard LevyEVPSell8,000$50.68$405,440.004,301View SEC Filing  
5/2/2014Laurent ChardonnetVPSell34,000$51.55$1,752,700.003,811View SEC Filing  
4/23/2014James DalyEVPSell30,555$47.71$1,457,779.05View SEC Filing  
2/20/2014Paul FriedmanDirectorSell33,354$63.51$2,118,312.54417,518View SEC Filing  
2/19/2014Paul FriedmanDirectorSell771,182$65.65$50,628,098.30417,518View SEC Filing  
2/19/2014Schutter Richard DeChairmanSell50,000$65.53$3,276,500.00155,000View SEC Filing  
2/18/2014David HastingsCFOSell275,000$65.86$18,111,500.008,500View SEC Filing  
9/10/2013Paul A FriedmanCEOSell376,789$37.32$14,061,765.48View SEC Filing  
9/9/2013Laurent ChardonnetVPSell44,834$37.31$1,672,756.54View SEC Filing  
9/6/2013David C HastingsCFOSell100,000$35.16$3,516,000.00View SEC Filing  
9/6/2013Richard S LevyEVPSell25,000$35.28$882,000.00View SEC Filing  
9/5/2013Paula J SwainEVPSell94,444$35.06$3,311,206.64View SEC Filing  
8/19/2013Roy WhitfieldDirectorSell50,000$26.70$1,335,000.00671,082View SEC Filing  
5/17/2013Roy A WhitfieldDirectorSell40,000$23.08$923,200.00View SEC Filing  
5/13/2013Richard S LevyEVPSell55,699$22.30$1,242,087.70View SEC Filing  
(Data available from 1/1/2013 forward)


Incyte (NASDAQ INCY) News Headlines

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY)SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Incyte Corporation (INCY) - April 20 at 5:18 PM
Incyte (INCY) Upgraded to Buy by BidaskClubIncyte (INCY) Upgraded to Buy by BidaskClub - April 20 at 12:13 PM
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCYSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Incyte Corporation - INCY - April 19 at 5:34 PM
Incyte (INCY) Downgraded by Zacks Investment ResearchIncyte (INCY) Downgraded by Zacks Investment Research - April 19 at 12:49 PM
ValuEngine Lowers Incyte (INCY) to Strong SellValuEngine Lowers Incyte (INCY) to Strong Sell - April 18 at 11:22 PM
Incyte (INCY) Lifted to Buy at Zacks Investment ResearchIncyte (INCY) Lifted to Buy at Zacks Investment Research - April 18 at 3:31 PM
Incyte (INCY) Given a $78.00 Price Target by Credit Suisse Group AnalystsIncyte (INCY) Given a $78.00 Price Target by Credit Suisse Group Analysts - April 18 at 8:47 AM
Whats Next for Incyte?What's Next for Incyte? - April 17 at 8:39 AM
Days After a Shocking Cancer Failure, Incyte Goes Back to WorkDays After a Shocking Cancer Failure, Incyte Goes Back to Work - April 16 at 5:17 PM
What Incyte's Phase 3 Fail Means for Immuno-OncologyWhat Incyte's Phase 3 Fail Means for Immuno-Oncology - April 16 at 5:17 PM
Incyte (INCY) and PRA Health Sciences (PRAH) Critical SurveyIncyte (INCY) and PRA Health Sciences (PRAH) Critical Survey - April 15 at 11:15 AM
What Happened With Incytes IDO Inhibitor FlopWhat Happened With Incyte's IDO Inhibitor Flop - April 14 at 8:28 AM
What Happened With Incyte's IDO Inhibitor FlopWhat Happened With Incyte's IDO Inhibitor Flop - April 14 at 8:28 AM
Industrials, airlines, energy & biotech in the blitzIndustrials, airlines, energy & biotech in the blitz - April 13 at 8:29 AM
Incyte to Report First Quarter Financial ResultsIncyte to Report First Quarter Financial Results - April 13 at 8:29 AM
$387.35 Million in Sales Expected for Incyte Co. (INCY) This Quarter$387.35 Million in Sales Expected for Incyte Co. (INCY) This Quarter - April 13 at 3:51 AM
Why GoPro, Incyte, and Wynn Resorts Jumped TodayWhy GoPro, Incyte, and Wynn Resorts Jumped Today - April 12 at 5:33 PM
Contrasting Incyte (INCY) and Syneos Health (SYNH)Contrasting Incyte (INCY) and Syneos Health (SYNH) - April 12 at 3:46 PM
Incyte (INCY) Stock Rating Upgraded by UBSIncyte (INCY) Stock Rating Upgraded by UBS - April 12 at 10:19 AM
-$0.12 EPS Expected for Incyte Co. (INCY) This Quarter-$0.12 EPS Expected for Incyte Co. (INCY) This Quarter - April 11 at 11:18 AM
Is Beaten-Down Incyte Corporation Stock a Buy Now?Is Beaten-Down Incyte Corporation Stock a Buy Now? - April 11 at 8:36 AM
Oppenheimer Weighs in on Incyte Co.s Q1 2018 Earnings (INCY)Oppenheimer Weighs in on Incyte Co.'s Q1 2018 Earnings (INCY) - April 11 at 8:05 AM
Acadia, Incyte Show the Way to Mondays 52-Week Low ClubAcadia, Incyte Show the Way to Monday's 52-Week Low Club - April 10 at 8:35 AM
Investors Buy Large Volume of Put Options on Incyte (INCY)Investors Buy Large Volume of Put Options on Incyte (INCY) - April 10 at 7:44 AM
Incyte's Epacadostat Fails in Melanoma Study, Shares PlungeIncyte's Epacadostat Fails in Melanoma Study, Shares Plunge - April 9 at 5:16 PM
Incyte Cancer Drug Flop Is Costly and Likely to Be DuplicatedIncyte Cancer Drug Flop Is Costly and Likely to Be Duplicated - April 9 at 5:16 PM
Cantor Fitzgerald Double Downgrades NewLink Genetics After Incytes Disappointing TrialCantor Fitzgerald Double Downgrades NewLink Genetics After Incyte's Disappointing Trial - April 9 at 5:16 PM
Incyte (INCY) Price Target Cut to $96.00 by Analysts at JPMorgan ChaseIncyte (INCY) Price Target Cut to $96.00 by Analysts at JPMorgan Chase - April 9 at 11:02 AM
Credit Suisse Group Trims Incyte (INCY) Target Price to $76.00Credit Suisse Group Trims Incyte (INCY) Target Price to $76.00 - April 9 at 9:56 AM
Incyte (INCY) Price Target Lowered to $76.00 at Morgan StanleyIncyte (INCY) Price Target Lowered to $76.00 at Morgan Stanley - April 9 at 9:55 AM
Incyte (INCY) Downgraded by GabelliIncyte (INCY) Downgraded by Gabelli - April 9 at 8:50 AM
Incyte Falls After Phase 3 Flop, But The Sky Isnt FallingIncyte Falls After Phase 3 Flop, But The Sky Isn't Falling - April 9 at 8:26 AM
[$$] Biotech Gets a Reality Check[$$] Biotech Gets a Reality Check - April 9 at 8:26 AM
Today’s Research Reports on Stocks to Watch: Incyte and MerckToday’s Research Reports on Stocks to Watch: Incyte and Merck - April 9 at 8:26 AM
Incyte (INCY) Price Target Lowered to $102.00 at NomuraIncyte (INCY) Price Target Lowered to $102.00 at Nomura - April 9 at 8:25 AM
Incyte (INCY) PT Set at $65.00 by OppenheimerIncyte (INCY) PT Set at $65.00 by Oppenheimer - April 9 at 7:54 AM
Incyte (INCY) Stock Rating Lowered by ValuEngineIncyte (INCY) Stock Rating Lowered by ValuEngine - April 7 at 10:26 AM
Your Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind OfferingYour Daily Pharma Scoop: Major Setback For Incyte, Aclaris Agreement, MannKind Offering - April 7 at 8:33 AM
Incyte Shares Tumble After Cancer Drug Fails in Trial With Mercks KeytrudaIncyte Shares Tumble After Cancer Drug Fails in Trial With Merck's Keytruda - April 7 at 8:33 AM
Incyte's Horrible News Derails a Promising Class of Cancer DrugsIncyte's Horrible News Derails a Promising Class of Cancer Drugs - April 7 at 8:33 AM
[$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck’s Keytruda[$$] Incyte Shares Tumble After Cancer Drug Fails in Trial With Merck’s Keytruda - April 7 at 8:33 AM
Incyte (INCY) Given Buy Rating at SunTrust BanksIncyte (INCY) Given Buy Rating at SunTrust Banks - April 6 at 9:16 PM
The Biggest Movers: Ventas Edges Up; Incyte PlungesThe Biggest Movers: Ventas Edges Up; Incyte Plunges - April 6 at 5:37 PM
NewLink will review clinical programs after Merck, Incyte trial failureNewLink will review clinical programs after Merck, Incyte trial failure - April 6 at 5:37 PM
Incyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopefulIncyte-Merck trial fails in blow to cancer immunotherapy, but researchers remain hopeful - April 6 at 5:13 PM
Incyte (INCY) Given a $85.00 Price Target by Raymond James Financial AnalystsIncyte (INCY) Given a $85.00 Price Target by Raymond James Financial Analysts - April 6 at 2:28 PM
Mid-Day Market Update: Dow Falls 350 Points; Incyte Shares PlungeMid-Day Market Update: Dow Falls 350 Points; Incyte Shares Plunge - April 6 at 1:37 PM
Incyte Corporation Stock Plunges on Melanoma Drug Trial FailureIncyte Corporation Stock Plunges on Melanoma Drug Trial Failure - April 6 at 12:30 PM
Incyte (INCY) Receives Neutral Rating from GuggenheimIncyte (INCY) Receives Neutral Rating from Guggenheim - April 6 at 10:59 AM
Incyte (INCY) Downgraded by William Blair to "Market Perform"Incyte (INCY) Downgraded by William Blair to "Market Perform" - April 6 at 10:44 AM

SEC Filings

Incyte (NASDAQ:INCY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Incyte (NASDAQ:INCY) Income Statement, Balance Sheet and Cash Flow Statement


Incyte (NASDAQ INCY) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.